Previous 10 | Next 10 |
Miragen Therapeutics (NASDAQ: MGEN ): Q1 GAAP EPS of -$0.18 beats by $0.03 . Revenue of $0.83M (+124.3% Y/Y) beats by $0.24M . Press Release More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020 Additional NIH grant funding released in support of MRG-229 for IPF; preclinical studies progressing as planned with additional data...
BOULDER, Colo., April 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the fina...
Miragen Therapeutics (NASDAQ: MGEN ) has filed a prospectus for a $175M mixed shelf offering. More news on: Miragen Therapeutics, Healthcare stocks news, , Stocks on the move, Read more ...
miRagen Therapeutics, Inc. (MGEN) Q4 2019 Earnings Conference Call March 11, 2020, 04:30 PM ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President and CEO Diana Escolar - Chief Medical Officer Jason Leverone - CFO Conference Call ...
Miragen Therapeutics (NASDAQ: MGEN ): Q4 GAAP EPS of -$0.31 misses by $0.06 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020 Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL patients; reported additional data in January 2020; expects to meet with the F...
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its fourth quarter and full year 2019 financial results ...
Gainers: Benitec Biopharma (NASDAQ: BNTC ) +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...
BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of ...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...